Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer

Share this content:
Improvement in diagnostic models and symptom recognition would aid early detection of pancreatic cancer.
Improvement in diagnostic models and symptom recognition would aid early detection of pancreatic cancer.

Measuring exhaled-breath volatile organic compounds (VOCs) has shown promise as a potential method for diagnosing patients with pancreatic cancer, according to a study published in the British Journal of Surgery

One of the greatest challenges in pancreatic cancer is early detection; as symptoms frequently overlap with other benign conditions, only 15% to 20% patients have curable disease at the time of diagnosis. There is a need for improvement in diagnostic models, symptom recognition, and predictive biomarkers. 

For this study, investigators enrolled 68 patients (25 with pancreatic cancer, 42 with no cancer) to their development cohort and 64 to their validation cohort (32 with pancreatic cancer, 32 with no cancer). In the development cohort, researchers analyzed the exhaled breath of participants using gas chromatography mass spectrometry to identify the difference in VOC concentrations among patients with cancer compared with the no-cancer controls.  

Overall, 66 VOCs were identified; 22 were excluded from further study as they were found in high concentrations in background air or were considered to be at a low likelihood of being produced endogenously. Of the remaining 44 VOCs, 12 were found to be significantly different among patients with pancreatic adenocarcinoma compared with patients without cancer. 

The concentration of 5 VOCs were considerably higher among cancer patients: formaldehyde, acetone, acetoin, undecane, and isopropyl alcohol. Seven VOCs (pentane,n-hexane, 1-butanol, 1-[methylthio]-propane, benzaldehyde, tetradecane, amylene hydrate) were found in lower concentrations among patients with cancer.

A receiver operating characteristic (ROC) curve analysis of the significant volatile compounds and the validation cohort showed good discrimination, resulting in an area under the curve of 0.736 (sensitivity, 81%; specificity, 58%) for differentiating cancer from no cancer, and 0.744 (sensitivity, 70%; specificity, 74%) for differentiating adenocarcinoma from no cancer.

Breath VOC-analysis may be a useful tool in distinguishing patients with pancreatic cancer from patients without the disease. The authors concluded that the “final application of breath testing in the patient care pathway will depend on test sensitivity and specificity in large multicenter clinical trials, and its performance in early pancreatic cancer and high-risk groups.”

Reference

Markar SR, Brodie B, Chin ST, Romano A, Spalding D, Hanna GB. Profile of exhaled-breath volatile organic compounds to diagnose pancreatic cancer[published online July 18, 2018]. Br J Surg. doi: 10.1002/bjs.10909

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs